Alessandro Larcher1, Christopher J D Wallis2, Axel Bex3, Michael L Blute4, Vincenzo Ficarra5, Arnaud Mejean6, Jose A Karam7, Hendrik Van Poppel8, Sumanta K Pal9. 1. Unit of Urology, Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy; ORSI Academy, Melle, Belgium; Department of Urology, Onze Lieve Vrouw Hospital, Aalst, Belgium. Electronic address: alelarcher@gmail.com. 2. ORSI Academy, Melle, Belgium; Department of Urology, Onze Lieve Vrouw Hospital, Aalst, Belgium; Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada. 3. Department of Urology, The Royal Free London NHS Foundation Trust and UCL Division of Surgery and Interventional Science, London, UK; Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. 4. Department of Urology, Harvard Medical School, Boston, MA, USA. 5. Urologic Section, Gaetano Barresi Department of Human and Pediatric Pathology, University of Messina, Messina, Italy. 6. Department of Urology, Hôpital Européen Georges Pompidou, Paris Descartes University, Paris, France. 7. Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 8. Department of Urology, University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Leuven, Belgium. 9. Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Abstract
CONTEXT: The current role of cytoreductive nephrectomy (CN) is controversial. OBJECTIVE: Review of the available evidence about criteria defining CN optimal candidates. EVIDENCE ACQUISITION: Collaborative critical narrative review of the literature focusing on CN oncological outcomes, perioperative morbidity, eligibility criteria, presurgical systemic therapy, and surgical factors. EVIDENCE SYNTHESIS: In contrast to observational studies, the Clinical Trial to Assess the Importance of Nephrectomy (CARMENA) trial demonstrated noninferiority of targeted therapy alone relative to CN with targeted therapy. CN is associated with a significant risk of perioperative mortality (0-13%) and major complications (3-36%). Metastatic burden, haematological parameters, performance status, sarcopenia, and genetic mutations have been proposed as CN eligibility criteria. Comprehensive models including local and systemic factors are recommended. The Immediate Surgery or Surgery after sunitinib Malate In Treating Patients with Kidney Cancer (SURTIME) trial reported similar progression-free rate after immediate or deferred CN, and suggests that presurgical systemic therapy can identify candidates for CN, avoiding unnecessary surgery in nonresponders without increasing the risk of perioperative complications. Minimally invasive and nephron-sparing CNs are established surgical strategies in selected patients. CONCLUSIONS: No benefit of upfront CN is observed for intermediate- and poor-risk patients who require systemic therapy in randomised controlled trials, and systemic therapy deserves priority over CN in patients with metastatic renal cell carcinoma. These findings are not applicable to all patients with metastatic kidney cancer. CN has a role in favourable cases not requiring immediate systemic therapy or in symptomatic patients. Individual patient selection to identify those patients who might profit the most from CN is critical; however, clinical decision making should be based on comprehensive models. Presurgical systemic therapy is a promising option to avoid unnecessary CN, which is associated with major morbidity. PATIENT SUMMARY: Consideration for systemic therapy deserves priority over cytoreductive nephrectomy (CN) in patients with metastatic renal cell carcinoma. In patients eligible for systemic therapy, CN does not offer a survival benefit. The indications for CN should be evaluated on an individual basis. Risk scores and response to presurgical systemic therapy can be used for subsequent decision making.
CONTEXT: The current role of cytoreductive nephrectomy (CN) is controversial. OBJECTIVE: Review of the available evidence about criteria defining CN optimal candidates. EVIDENCE ACQUISITION: Collaborative critical narrative review of the literature focusing on CN oncological outcomes, perioperative morbidity, eligibility criteria, presurgical systemic therapy, and surgical factors. EVIDENCE SYNTHESIS: In contrast to observational studies, the Clinical Trial to Assess the Importance of Nephrectomy (CARMENA) trial demonstrated noninferiority of targeted therapy alone relative to CN with targeted therapy. CN is associated with a significant risk of perioperative mortality (0-13%) and major complications (3-36%). Metastatic burden, haematological parameters, performance status, sarcopenia, and genetic mutations have been proposed as CN eligibility criteria. Comprehensive models including local and systemic factors are recommended. The Immediate Surgery or Surgery after sunitinib Malate In Treating Patients with Kidney Cancer (SURTIME) trial reported similar progression-free rate after immediate or deferred CN, and suggests that presurgical systemic therapy can identify candidates for CN, avoiding unnecessary surgery in nonresponders without increasing the risk of perioperative complications. Minimally invasive and nephron-sparing CNs are established surgical strategies in selected patients. CONCLUSIONS: No benefit of upfront CN is observed for intermediate- and poor-risk patients who require systemic therapy in randomised controlled trials, and systemic therapy deserves priority over CN in patients with metastatic renal cell carcinoma. These findings are not applicable to all patients with metastatic kidney cancer. CN has a role in favourable cases not requiring immediate systemic therapy or in symptomatic patients. Individual patient selection to identify those patients who might profit the most from CN is critical; however, clinical decision making should be based on comprehensive models. Presurgical systemic therapy is a promising option to avoid unnecessary CN, which is associated with major morbidity. PATIENT SUMMARY: Consideration for systemic therapy deserves priority over cytoreductive nephrectomy (CN) in patients with metastatic renal cell carcinoma. In patients eligible for systemic therapy, CN does not offer a survival benefit. The indications for CN should be evaluated on an individual basis. Risk scores and response to presurgical systemic therapy can be used for subsequent decision making.
Authors: Giuseppe Rosiello; Sophie Knipper; Carlotta Palumbo; Cristina Dzyuba-Negrean; Angela Pecoraro; Elio Mazzone; Francesco A Mistretta; Zhe Tian; Umberto Capitanio; Francesco Montorsi; Shahrokh F Shariat; Fred Saad; Alberto Briganti; Pierre I Karakiewicz Journal: Int Urol Nephrol Date: 2019-08-29 Impact factor: 2.370
Authors: Giuseppe Rosiello; Carlotta Palumbo; Sophie Knipper; Angela Pecoraro; Stefano Luzzago; Pierre-Antoine St-Hilaire; Zhe Tian; Umberto Capitanio; Francesco Montorsi; Shahrokh F Shariat; Fred Saad; Alberto Briganti; Pierre I Karakiewicz Journal: World J Urol Date: 2020-04-06 Impact factor: 4.226
Authors: Giuseppe Rosiello; Angela Pecoraro; Marina Deuker; Lara Franziska Stolzenbach; Thomas Martin; Zhe Tian; Alessandro Larcher; Umberto Capitanio; Francesco Montorsi; Shahrokh F Shariat; Anil Kapoor; Fred Saad; Alberto Briganti; Pierre I Karakiewicz Journal: Int J Clin Oncol Date: 2021-01-30 Impact factor: 3.402
Authors: Mary E Hall; Bimal Bhindi; Amy N Luckenbaugh; Aaron A Laviana; Kelvin A Moses; Raj Satkunasivam; Brian Rini; Zachary Klaassen; Christopher J D Wallis Journal: Cancer Causes Control Date: 2021-05-08 Impact factor: 2.506
Authors: Renzo G DiNatale; Wanling Xie; Maria F Becerra; Andrew W Silagy; Kyrollis Attalla; Alejandro Sanchez; Roy Mano; Julian Marcon; Kyle A Blum; Nicole E Benfante; Martin H Voss; Robert J Motzer; Jonathan Coleman; Toni K Choueiri; Ed Reznik; Paul Russo; Daniel Y C Heng; A Ari Hakimi Journal: Eur Urol Oncol Date: 2019-11-14